Patient characteristics of all patients at baseline and 1-year values in patients in clinical remission after 1 year; dichotomous variables presented as N (%), continuous variables presented as mean (SD)
| Variable | Baseline values, all patients (n=218) | 1-year values, patients in remission at 1 year (n=164) |
| Age in years | 51.7 (13.6) | 52.2 (13.7) |
| Female gender | 137 (63%) | 96 (59%) |
| Body mass index (kg/m2) | 25.7 (4.4) | 25.3 (4.1) |
| Current smoking | 52 (24%) | 38 (23%) |
| Time from disease onset to inclusion (days) | 213 (161) | 211 (163) |
| ACPA-positive | 180 (83%) | 134 (82%) |
| RF positive (IgA or IgM) | 155 (71%) | 114 (70%) |
| Disease Activity Score (44 joints) | 3.4 (1.1) | 0.9 (0.4) |
| Simplified Disease Activity Index | 24.3 (12.6) | 2.2 (1.9) |
| Patient global assessment (VAS 0–100 mm) | 49.3 (24.3) | 10.5 (13.3) |
| Physician global assessment (VAS 0–100 mm) | 39.7 (20.2) | 5.0 (4.5) |
| Swollen joint count (44 joints) | 10.2 (7.1) | 0.2 (0.6) |
| Total Richie score | 8.5 (7.0) | 0.4 (0.7) |
| Erythrocyte sedimentation rate (mm/hour) | 24.6 (18.5) | 9.7 (7.1) |
| C reactive protein (mg/L) | 15.1 (20.3) | 3.4 (3.3) |
| Calprotectin (µg/L) | 2123.8 (4221.1) | – |
| Joint pain (VAS 0–100 mm) | 47.0 (23.6) | 9.6 (13.3) |
| Van der Heijde modified Sharp JSN score | 2.6 (3.9) | 2.8 (4.1) |
| Van der Heijde modified Sharp erosion score | 3.8 (3.6) | 4.6 (4.2) |
| Van der Heijde modified Sharp total score | 6.4 (6.7) | 7.4 (7.3) |
Calprotectin only measured at baseline.
ACPA, anti-citrullinated peptide antibody; JSN, joint space narrowing; RF, rheumatoid factor; VAS, Visual Analogue Scale.